Key Takeaways
- FDA issued its second rejection of Replimune’s RP1 immunotherapy for treating advanced melanoma
- The treatment was under review for use alongside Bristol Myers Squibb’s (BMY) Opdivo
- Regulators maintained their position that the clinical trial lacked adequate controls
- REPL shares plummeted approximately 19% to $4.76, with two volatility-triggered trading halts
- The current price represents a significant decline from its 52-week peak of $13.24
Replimune (REPL) has encountered a significant setback as the FDA denied approval for its RP1 therapy for the second consecutive time, maintaining its position on clinical trial design inadequacies.
The regulatory agency delivered a complete response letter rejecting vusolimogene oderparepvec (RP1) for administration in combination with Bristol Myers Squibb’s (BMY) Opdivo in patients with advanced melanoma who previously underwent anti-PD-1 therapy.
In correspondence directed to Kari Jeschke, Replimune’s senior vice president of regulatory affairs, the FDA indicated that supplementary exploratory analyses of the trial data failed to change its previous determination. The agency concluded that the RPL-001-16 trial did not meet standards as an adequate and well-controlled clinical study.
Notably, the FDA expressed no safety-related objections to the drug — the primary concern centers entirely on insufficient efficacy data.
This marks the second time regulators have turned down the application. The initial rejection occurred in July 2025, following Vinay Prasad’s appointment to head the FDA’s Center for Biologics Evaluation and Research two months earlier. Replimune subsequently resubmitted its Biologics License Application, receiving acceptance for review in October 2025.
REPL shares declined roughly 19% to reach $4.76 following the announcement. The session saw two trading suspensions triggered by extreme volatility. This price level positions the stock toward its lowest closing point since October, based on Dow Jones Market Data.
At the current valuation, REPL trades substantially below its 52-week pinnacle of $13.24.
Understanding RP1 Therapy
RP1 represents a genetically modified variant of Herpes Simplex Virus type 1 — the identical virus responsible for cold sores. Replimune engineered it to replicate exclusively within cancerous cells, destroying them upon replication while simultaneously activating enhanced immune responses from the body’s white blood cell population.
The therapy serves as the flagship asset within Replimune’s RPx platform, which concentrates on developing oncolytic immunotherapies targeting solid tumors.
The biotechnology company currently maintains a market capitalization of approximately $393 million. No price-to-earnings ratio exists due to negative earnings — a typical situation for clinical-stage biotech firms developing their therapeutic pipelines.
Insider Transactions and Company Fundamentals
Replimune’s GF Score registers at 40 out of 100, with profitability metrics scoring merely 1 out of 10. The company’s financial strength assessment reaches 6 out of 10.
During the preceding three-month period, company insiders disposed of $0.1 million in stock holdings, with zero purchases documented.
Shares currently trade at $4.76, significantly beneath the 52-week maximum of $13.24 achieved earlier this year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
